Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hayder Saeed is active.

Publication


Featured researches published by Hayder Saeed.


Journal of Drug Targeting | 2010

Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by aids viruses

Abeer M. Al-Ghananeem; Hayder Saeed; Rebecca L. Florence; Robert A. Yokel; Ahmad H. Malkawi

The primary aim of this study was to investigate intranasal (i.n.) administration as a potential route to enhance systemic and brain delivery of didanosine (ddI). A further aim was to investigate the potential use of chitosan nanoparticles as a delivery system to enhance the systemic and brain targeting efficiency of ddI following i.n. administration. Didanosine-loaded chitosan nanoparticles, were prepared through ionotropic gelation of chitosan with tripolyphosphonate anions, and characterized in terms of their size, drug loading, and in vitro release. The nanoparticles were administered i.n. to rats, compared to i.n. and intravenous (i.v.) administration of ddI in solution. The concentrations of ddI in blood, CSF, and brain tissues were analyzed by ultra performance liquid chromatography mass spectroscopy (UPLC/MS). The brain/plasma, olfactory bulb/plasma and CSF/plasma concentration ratios were significantly higher (P < 0.05) after i.n. administration of ddI nanoparticles or solution than those after i.v. administration of didanosine aqueous solution. The ratio of ddI concentration values of the nanoparticles to the solution at 180 min post-i.n. dosing was 2.1 and 1.9 in CSF and brain, respectively. Thus, both the i.n. route of administration and formulation of ddI in chitosan nanoparticles increased delivery of ddI to CSF and brain.


The New England Journal of Medicine | 2012

Images in clinical medicine. Hypertrophic pulmonary osteoarthropathy and tripe palms.

Hayder Saeed; Suleiman Massarweh

A 56-year-old female smoker presented with cough, a weight loss of 27 kg, and diffuse bone pain. There was digital clubbing, and the palms had a raised, velvety texture. There was a fixed, tender lump (4 cm in diameter) on the right lower leg and one over the lower lumbar spine.


Journal of Surgical Oncology | 2016

Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis

Hayder Saeed; Dima Hnoosh; Bin Huang; Eric B. Durbin; Patrick C. McGrath; Philip A. DeSimone; Erin Maynard; Lowell B. Anthony; Sean P. Dineen; Peter J. Hosein; Ching Wei D. Tzeng

Long‐term results of the ESPAC‐3 trial suggest that while completing adjuvant therapy (AT) is necessary after resection of pancreatic ductal adenocarcinoma (PDAC), early initiation (within 8 weeks) may not be associated with improved overall survival (OS). The primary aim of this study was to evaluate the OS impact of early versus late AT in a statewide analysis.


Rare Tumors | 2014

Blastic Plasmacytoid Dendritic Cell Neoplasm with Extensive Cutaneous and Central Nervous System Involvement

Hayder Saeed; Mukta Awasthi; Abeer Al-Qaisi; Suleiman Massarweh

Blastic plasmacytoid dendritic neoplasm is an exceedingly rare tumor that has undergone several changes in nomenclature over the last two decades, largely because of confusion regarding its cell of origin. It does, however, have distinctive clinical features with a particularly aggressive clinical course and no standard treatment. Overall, prognosis is poor and relapse is routine after initial response to chemotherapy. In this report, we describe a typical patient with this disease and reconcile the available literature and its evolution. We emphasize the leukemic nature of this tumor’s behavior, with extensive central nervous system and skin involvement, and describe for the first time a potential role for maintenance chemotherapy in its treatment.


Annals of Hematology | 2018

Copper deficiency anemia: review article

Zin W. Myint; Thein H. Oo; Kyaw Zin Thein; Aung Myint Tun; Hayder Saeed

Copper is a crucial micronutrient needed by animals and humans for proper organ function and metabolic processes such as hemoglobin synthesis, as a neurotransmitter, for iron oxidation, cellular respiration, and antioxidant defense peptide amidation, and in the formation of pigments and connective tissue. Multiple factors, either hereditary or acquired, contribute to the increase in copper deficiency seen clinically over the past decades. The uptake of dietary copper into intestinal cells is via the Ctr1 transporter, located at the apical membrane aspect of intestinal cells and in most tissues. Copper is excreted from enterocytes into the blood via the Cu-ATPase, ATP7A, by trafficking the transporter towards the basolateral membrane. Zinc is another important micronutrient in animals and humans. Although zinc absorption may occur by direct interaction with the Ctr1 transporter, its absorption is slightly different. Copper deficiency affects physiologic systems such as bone marrow hematopoiesis, optic nerve function, and the nervous system in general. Detailed pathophysiology and its related diseases are explained in this manuscript. Diagnosis is made by measuring serum copper, serum ceruloplasmin, and 24-h urine copper levels. Copper deficiency anemia is treated with oral or intravenous copper replacement in the form of copper gluconate, copper sulfate, or copper chloride. Hematological manifestations are fully reversible with copper supplementation over a 4- to 12-week period. However, neurological manifestations are only partially reversible with copper supplementation.


Hematology/Oncology and Stem Cell Therapy | 2018

Age adjusted hematopoietic stem cell transplant comorbidity index predicts survival in a T-cell depleted cohort

Hayder Saeed; Swati Yalamanchi; Meng Liu; Emily Van Meter; Zartash Gul; Gregory Monohan; Dianna Howard; Gerhard C. Hildebrandt; Roger Herzig

OBJECTIVES Allogeneic hematopoietic stem cell transplant (HCT) continues to evolve with the treatment in higher risk patient population. This practice mandates stringent update and validation of risk stratification prior to undergoing such a complex and potentially fatal procedure. We examined the adoption of the new comorbidity index (HCT-CI/Age) proposed by the Seattle group after the addition of age variable and compared it to the pre-transplant assessment of mortality (PAM) that already incorporates age as part of its evaluation criteria. METHODS A retrospective analysis of adult patients who underwent HCT at our institution from January 2010 through August 2014 was performed. Kaplan-Meiers curve, log-rank tests, Cox model and Pearson correlation was used in the analysis. RESULTS Of the 114 patients that underwent allogeneic transplant in our institution, 75.4% were ≥40 years old. More than 58% had a DLCO ≤80%. Although scores were positively correlated (correlation coefficient 0.43, p < 0.001), HCT-CI/Age more accurately predicted 2-year overall survival (OS) and non-relapse mortality (NRM) in patients with lower (0-4) and higher (5-7) scores (52% and 36% versus 24% and 76%, p = 0.004, 0.003 respectively). PAM score did not reach statistical significance for difference in OS nor NRM between the low (<24) and high-risk (≥24) groups (p = 0.19 for both). CONCLUSIONS Despite our small sample population, HCT-CI/Age was more discriminative to identify patients with poor outcome that might benefit from intensified management strategies or other therapeutic approaches rather than allogeneic HCT.


Hematology/Oncology and Stem Cell Therapy | 2017

Multimodality therapy improves survival in intramedullary spinal cord metastasis of lung primary

Hayder Saeed; Reema Patel; Jigisha P. Thakkar; Lames Hamoodi; Li Chen; John L. Villano

BACKGROUND Most metastatic spinal cord lesions are located either in the intradural, extramedullary, or in the epidural compartments. Intramedullary spinal cord metastasis (ISCM) is a rare central nervous system spread of cancer. The aim of this report was to evaluate ISCM in the published literature. METHODS A literature review of PubMed from 1960 to 2016 was undertaken for the publications having demographic, clinical, histological, and outcome data. RESULTS A total of 59 relevant papers were identified, showing 128 cases of intramedullary metastasis from lung cancer. The incidence of lung cancer as the primary malignancy with intramedullary metastasis was 56%. The median time from diagnosis of primary to intramedullary metastasis was 6months. Survival improved with multimodality therapy compared to monotherapy (4monthsvs. 6.3months) (hazard ratio=0.501; 95% confidence interval, 0.293-0.857). CONCLUSION Lung cancer is the predominant cause of intramedullary involvement of the spinal cord. Overall prognosis is poor, although a multimodality approach was associated with improved survival.


International Journal of Hematology | 2015

Evaluating the optimal serum ferritin level to identify hemophagocytic lymphohistiocytosis in the critical care setting

Hayder Saeed; Ryan Woods; Joshua D. Lester; Roger Herzig; Zartash Gul; Gregory Monohan


Breast Cancer Research and Treatment | 2012

A prognostic model of early breast cancer relapse after standard adjuvant therapy and comparison with metastatic disease on initial presentation

Li Chen; Edward H. Romond; Saurin Chokshi; Hayder Saeed; Jacob Hodskins; M Stevens; G Pasley; Heidi L. Weiss; Suleiman Massarweh


Journal of Surgical Research | 2017

Effect of complications on oncologic outcomes after pancreaticoduodenectomy for pancreatic cancer

Anh-Thu Le; Bin Huang; Dima Hnoosh; Hayder Saeed; Sean P. Dineen; Peter J. Hosein; Eric B. Durbin; Mahesh Kudrimoti; Patrick C. McGrath; Ching Wei D. Tzeng

Collaboration


Dive into the Hayder Saeed's collaboration.

Top Co-Authors

Avatar

Bin Huang

University of Kentucky

View shared research outputs
Top Co-Authors

Avatar

Dima Hnoosh

University of Kentucky

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge